Helicobacter pylori and Nonmalignant Diseases

Keyphrases

• Bleeding 20%
• Bleeding Peptic Ulcer 20%
• Chronic Users 20%
• Clinical Decisions 20%
• Consensus Document 20%
• Disease Entity 20%
• Disease Symptoms 40%
• Duodenal Ulcer 40%
• Dyspepsia 40%
• Functional Dyspepsia 60%
• Gastric Ulcer 40%
• Gastroesophageal Reflux Disease 60%
• Helicobacter Pylori (H. pylori) 100%
• Helicobacter Pylori Eradication 40%
• Helicobacter Pylori Infection 60%
• Hospitalization Rate 20%
• Intervention Studies 20%
• Long-term Intervention 20%
• Non-cancer 100%
• Non-steroidal Anti-inflammatory Drugs (NSAIDs) 20%
• Patients with Functional Dyspepsia 20%
• Peptic Perforation 20%
• Peptic Ulcer Disease 20%
• Proton Pump Inhibitors 20%
• Quality of Life 20%
• Reflux Esophagitis 20%
• Risk Reduction 20%
• Significant Benefit 20%
• Ulcer Disease 20%
• Western Population 20%

Medicine and Dentistry

• Base 14%
• Bleeding 14%
• Disease 100%
• Duodenum Ulcer 28%
• Dyspepsia 85%
• Gastroesophageal Reflux 42%
• Helicobacter 14%
• Helicobacter Infection 14%
• Helicobacter Pylori 100%
• Infection 28%
• Intervention Study 14%
• Jejunum Ulcer 14%
• Nonsteroid Antiinflammatory Agent 14%
• Peptic Ulcer Bleeding 14%
• Proton-Pump Inhibitor 14%
• Pylorus 100%
• Quality of Life 14%
• Reflux Esophagitis 14%
• Stomach Ulcer 28%
• Symptom 57%
• Ulcer 14%

Pharmacology, Toxicology and Pharmaceutical Science

• Base 16%
• Bleeding 16%
• Disease 100%
• Duodenum Ulcer 33%
• Dyspepsia 100%
• Gastroesophageal Reflux 50%
• Helicobacter 16%
• Helicobacter Infection 16%
• Helicobacter Pylori 100%
• Infection 33%
• Intervention Study 16%
• Jejunum Ulcer 16%
• Non-Steroidal Anti-Inflammatory Drug 16%
• Peptic Ulcer Bleeding 16%
• Proton Pump Inhibitor 16%
• Reflux Esophagitis 16%
• Stomach Ulcer 33%
• Symptom 66%
• Ulcer 16%